What you missed in February: biotech investing analysis, NIH policy explainers, and breaking news

Get 25% off an annual STAT+ subscription and read more of our award-winning journalism.

My Account    STAT+ Check out last month's top stories. If you like what you see, join the STAT+ community today – and enjoy 25% off your first year with code LOYAL25. Adam Feuerstein/STAT 1   Biotech is in a dark place By Adam Feuerstein Photo illustration: Christine Kao/STAT; Photos: Adobe 2   The CRISPR companies are not OK By Jason Mast Photo illustration: Christine Kao/STAT; Photo: Adobe 3   Two biotechs say they're using AI to conjure drugs from scratch. Their documents suggest otherwise By Brittany Trang 25% off STAT+ Get 25% off your first year of STAT+ with discount code LOYAL25. SUBSCRIBE NOW More Top Stories 4   What are indirect research costs? A quick explainer in light of NIH's sweeping policy change By Jonathan Wosen and Angus Chen 5   NIH plans to slash support for indirect research costs, sending shockwaves through science By Jonathan Wosen, Megan Molteni, Jason Mast, and Usha Lee McFarling 6   Here's how big a hit some universities may take if NIH slashes support for indirect research costs By Angus Chen and Jonathan Wosen 7   Second top NIH official, who oversaw awarding of research grants, departs abruptly By Sarah Owermohle and Lev Facher 8   How much weight loss is too much? Pharma is pushing the limit with new obesity drugs By Elaine Chen 9   Why biotech's future is threatened by zombies By Adam Feuerstein 10   Federal judge halts Trump administration cuts to NIH research payments in 22 states By Jonathan Wosen and Angus Chen read more STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us